Endocare Joins Russell Microcap Index

IRVINE, Calif., July 1 /PRNewswire-FirstCall/ -- Endocare, Inc.
(Nasdaq: ENDO), an innovative medical device company providing minimally
invasive technologies for tissue and tumor ablation, announced today that
it has joined the Russell Microcap Index.

Introduced in 2005, the Russell Microcap Index measures the performance
of the microcap segment of the U.S. equity markets and includes 1,000 of
the smallest securities in the small-cap Russell 2000(R) Index and the next
1,000 securities -- in descending order by market capitalization -- trading
on national exchanges. The index offers analysts, portfolio managers and
other investors a comprehensive, unbiased benchmark by which to compare
their performance.

Russell annually reconstitutes its market cap-weighted indexes to
reflect changes in the market over time and provide representative
investment opportunity-sets for institutional managers. This year's list of
additions to the microcap index is at
http://www.russell.com/indexes/membership/Reconstitution/Recon_microcap_additions.
asp Reconstitution of all Russell indexes occurred after the U.S. equity
markets closed on June 27.

Endocare Chairman, President, and Chief Executive Officer Craig
Davenport remarked, "Our addition to the Russell Microcap Index is a result
of the dedicated work of our employees and represents another important
step in growing our presence and visibility in the investment community. We
expect that inclusion in the index will also raise our profile among
institutional and other investors who use the index as part of their
investment strategies."

Over the past 25 years, Russell indexes have become the benchmarks most
widely used by institutional investment managers as well as investors in
index funds. Currently, more than $4.4 trillion is managed by institutional
investors who use Russell indexes as benchmarks to guide their
decision-making for both passive and active investment strategies.
Investment managers utilize indexes as their portfolios purchase shares of
the companies in the indexes according to relative index-weightings.

On May 30, 2008, all eligible securities were ranked by their total
market capitalization. Companies whose stocks are listed on eligible
national stock exchanges and which pass minimum liquidity and other
investability rules were considered for inclusion in the indexes. The list
of preliminary additions was published on June 13 and subsequently updated
on June 20 and June 27.

About Russell

Russell Investments provides strategic advice, world-class
implementation, state-of-the-art performance benchmarks and a range of
institutional-quality investment products. Russell has more than $213
billion in assets under management as of March 31, 2008, and serves
individual, institutional and advisor clients in more than 40 countries.
Founded in 1936, Russell is a subsidiary of The Northwestern Mutual Life
Insurance Company.

About Endocare

Endocare, Inc. -- http://www.endocare.com -- is an innovative medical
device company providing minimally invasive technologies for tissue and
tumor ablation. Endocare has initially concentrated on developing
technologies for the treatment of prostate cancer and believes that its
proprietary technologies have broad applications across a number of
markets, including the ablation of tumors in the kidney, lung and liver and
palliative intervention (treatment of pain associated with metastases).

Statements contained in this press release that are not historical
facts are forward-looking statements that involve risks and uncertainties.
These forward-looking statements, include, but are not limited to,
statements regarding the possible effects of the Company joining the
Russell Microcap Index. Actual results may differ materially from any
forward-looking statements due to such risks and uncertainties. These risks
and uncertainties include, but are not limited to, those discussed in "Risk
Factors" in the Company's Forms 10-K, Forms 10-Q and other filings with the
U.S. Securities and Exchange Commission. The Company undertakes no
obligation to revise, or update publicly, any forward-looking statements
for any reason.



Investor Contact: Media Contact: For Additional
Matt Clawson Len Hall Information:
Allen & Caron, Inc. Allen & Caron, Inc. Craig T. Davenport, CEO
(949) 474-4300 (949) 474-4300 Michael R. Rodriguez, CFO
matt@allencaron.com len@allencaron.com Endocare, Inc.
(949) 450-5400

See Also:

• eLifeCare Solutions Successfully Demonstrates Interoperability of Patient Medical Data for Healthcare Providers



• Luxurious, Eco-Friendly Skin Care For Baby and Mommy!



• Give Up Chemical Dependency and Gain A New Perspective on Life!



• Some Useful Ideas on Real Estate can help newbie’s in real estate business



• Novelle International Announces Spokesman Agreement With Dr. Ward Bond

[Via Healthcare]